SIGA’s strategy is focused on delivering long-term shareholder value.
To achieve this, the Company has concentrated its efforts in four
pivotal areas to drive growth. These priorities include continuing our
partnership with the U.S. Government, advancing regulatory approvals for
TPOXX in new indications and formulations, cultivating strategic
partnerships to expand global access to TPOXX, and leveraging our
capabilities to move into complementary therapeutic areas.
For more information, please see
SIGA’s management presentation.